Niepublicznego Zakladu Opieki Zdrowotnej Specjalistyczny Osrodek Internistyczno Diabetologiczny
- Address
- lock Available on a paid plan
Type 2 Diabetes Management
The centre in Bialystok conducts studies aimed at improving glycaemic control in adults with type 2 diabetes, exploring both injectable and oral therapies.
- Weekly basal insulin switched from daily regimens
- Oral agents targeting blood sugar reduction
- Combination of insulin with non‑insulin drugs
- Safety and tolerability assessments
These trials reflect the site’s focus on advancing diabetes care while supporting patients in everyday management.
Obesity and Weight Management
Research at the facility includes investigations into effective strategies for individuals who are overweight or obese without diabetes, seeking sustainable weight loss.
- Novel agents influencing body weight
- Long‑term percentage change in body weight
- Impact on metabolic health markers
- Patient‑reported outcomes on quality of life
The work supports the centre’s commitment to tackling metabolic disease through innovative therapies.
Kidney Protection in Diabetes
Studies are evaluating how new treatments can slow the progression of chronic kidney disease in people with type 2 diabetes who are also overweight.
- Surrogate markers of renal decline
- Comparison of combination therapy versus monocomponents
- Role of weight reduction on kidney outcomes
- Integration of metabolic and renal health assessments
The Niepublicznego Zakladu Opieki Zdrowotnej Specjalistyczny Osrodek Internistyczno Diabetologiczny leverages its expertise to address this high‑risk population.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Novo Nordisk A/S1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S4trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Niepublicznego Zakladu Opieki Zdrowotnej Specjalistyczny Osrodek Internistyczno Diabetologiczny
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Weekly Insulin Icodec Versus Daily Insulin Glargine in Adults with Type 2 Diabetes Transitioning from Basal Insulin | Novo Nordisk A/S | Phase III | Not Recruiting | Apr 2024 | Jun 2025 |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Semaglutide | 4 | Unknown | 2023-11-07 | 2026-05-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.